Contrasting Boston Scientific Corporation (BSX) and Its Peers
Boston Scientific Corporation (NYSE: BSX) is one of 83 publicly-traded companies in the “Advanced Medical Equipment & Technology” industry, but how does it contrast to its competitors? We will compare Boston Scientific Corporation to related businesses based on the strength of its profitability, analyst recommendations, earnings, risk, dividends, institutional ownership and valuation.
Insider and Institutional Ownership
90.5% of Boston Scientific Corporation shares are owned by institutional investors. Comparatively, 51.1% of shares of all “Advanced Medical Equipment & Technology” companies are owned by institutional investors. 0.7% of Boston Scientific Corporation shares are owned by insiders. Comparatively, 18.7% of shares of all “Advanced Medical Equipment & Technology” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
This is a summary of recent recommendations for Boston Scientific Corporation and its competitors, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Boston Scientific Corporation||0||4||13||0||2.76|
|Boston Scientific Corporation Competitors||267||1850||3312||105||2.59|
Boston Scientific Corporation presently has a consensus price target of $31.11, suggesting a potential upside of 10.54%. As a group, “Advanced Medical Equipment & Technology” companies have a potential downside of 7.06%. Given Boston Scientific Corporation’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Boston Scientific Corporation is more favorable than its competitors.
This table compares Boston Scientific Corporation and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Boston Scientific Corporation||9.55%||23.60%||9.24%|
|Boston Scientific Corporation Competitors||-328.39%||-35.89%||-12.62%|
Risk & Volatility
Boston Scientific Corporation has a beta of 1, suggesting that its share price has a similar volatility profile to the S&P 500.Comparatively, Boston Scientific Corporation’s competitors have a beta of 0.90, suggesting that their average share price is 10% less volatile than the S&P 500.
Earnings and Valuation
This table compares Boston Scientific Corporation and its competitors revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Boston Scientific Corporation||$8.71 billion||$2.31 billion||46.13|
|Boston Scientific Corporation Competitors||$2.06 billion||$438.96 million||-76.08|
Boston Scientific Corporation has higher revenue and earnings than its competitors. Boston Scientific Corporation is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Boston Scientific Corporation beats its competitors on 11 of the 13 factors compared.
About Boston Scientific Corporation
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology. It operates in three segments: Cardiovascular, Rhythm Management and MedSurg. Its Cardiovascular segment consists of Interventional Cardiology and Peripheral Interventions businesses. Rhythm Management consists of Cardiac Rhythm Management and Electrophysiology businesses. MedSurg consists of Endoscopy, Urology and Pelvic Health, and Neuromodulation businesses. Its Interventional Cardiology product offerings include balloon catheters, rotational atherectomy systems, guide wires, guide catheters and embolic protection devices and diagnostic catheters used in percutaneous transluminal coronary angioplasty (PTCA) procedures.
Receive News & Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with MarketBeat.com's FREE daily email newsletter.